Introduction International registries provide opportunities to describe use of biologics for
treating severe asthma in current clinical practice. Our aims were to describe real-life global …

Background Patients with severe asthma may remain uncontrolled despite biologic therapy
in addition to standard therapy, but this disease burden has not been quantified. Objective …

Background Patients with severe asthma (SA) have a heightened risk of exacerbations
including hospitalization. The real-world, specialist-verified incidence and characteristics of …

Objective: The objective of the present study was to determine the use of systemic
corticosteroids (SCs) in patients with bronchial asthma using big data analysis. Methods: We …

Background There is a need for new and effective oral asthma therapies. Dexpramipexole,
an oral eosinophil-lowering drug, has not previously been studied in asthma. Objective We …

Background: Patients with severe uncontrolled asthma (SUA) overwhelmingly contribute to
the economic burden of asthma and may require biologic therapy. However, the impact of …

Background Notwithstanding unequivocal consensus on the disproportionate effect of
severe asthma (SA) on asthma morbidity, healthcare utilization, quality of life, work …

Objective For patients with severe asthma (SA), overestimation of asthma control may lead
to poorer outcomes. The objective of this study was to assess concurrent patient and …

Background Patients with severe asthma (SA) experience a high disease burden, often
precipitated by exposure to disease triggers. Objective To evaluate the prevalence and …

Background: We recently reported that severe asthma patients with frequent exacerbations
showed high blood eosinophil counts (Eo) and fractions of exhaled nitric oxide (FeNO) …